Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Int J Immunopathol Pharmacol ; 26(2): 327-35, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-23755748

RESUMO

Vascular endothelial growth factor (VEGF) is one of the most important inducers of angiogenesis, therefore blocking angiogenesis has led to great promise in the treatment of various cancers and inflammatory diseases. VEGF, expressed in response to soluble mediators such as cytokines and growth factors, is important in the physiological development of blood vessels as well as development of vessels in tumors. In cancer patients VEGF levels are increased, and the expression of VEGF is associated with poor prognosis in diseases. VEGF is a mediator of angiogenesis and inflammation which are closely integrated processes in a number of physiological and pathological conditions including obesity, psoriasis, autoimmune diseases and tumor. Mast cells can be activated by anti-IgE to release potent mediators of inflammation and can also respond to bacterial or viral antigens, cytokines, growth factors and hormones, leading to differential release of distinct mediators without degranulation. Substance P strongly induces VEGF in mast cells, and IL-33 contributes to the stimulation and release of VEGF in human mast cells in a dose-dependent manner and acts synergistically in combination with Substance P. Here we report a strong link between VEGF and mast cells and we depict their role in inflammation and immunity.


Assuntos
Inflamação/metabolismo , Mastócitos/metabolismo , Fator A de Crescimento do Endotélio Vascular/metabolismo , Animais , Citocinas/metabolismo , Humanos , Inflamação/imunologia , Inflamação/fisiopatologia , Mediadores da Inflamação/metabolismo , Mastócitos/imunologia , Neovascularização Patológica , Neovascularização Fisiológica , Transdução de Sinais
2.
J Biol Regul Homeost Agents ; 27(1): 1-7, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-23489682

RESUMO

Inflammation is involved in increasing number of diseases necessitating the development of new, effective and safe treatments. Non steroidal anti-inflammatory drugs (NSAIDs) have been helpful in many instances, but they only inhibit cyclooxygenase (COX), but not the generation or actions of cytokines. Instead, some natural flavonoids have multiple anti-inflammatory effects, including COX inhibition, and a much safer profile. Increasing evidence indicates that inflammation plays a critical role in the pathogenesis of many diseases that also involve mast cells. Consequently, the need for new, effective and safe anti-inflammatory drugs is all the more urgent. Corticosteroids are quite potent, but have many adverse effects such as increased risk of infections, osteoporosis, glaucoma and depression. Biological agents such anti-TNF are useful in certain conditions, such as rheumatoid arthritis and psoriasis, but has been associated with increased risk of infection and leukemia.


Assuntos
Anti-Inflamatórios não Esteroides/farmacologia , Flavonoides/farmacologia , Animais , Anti-Inflamatórios não Esteroides/uso terapêutico , Flavonoides/uso terapêutico , Humanos , Inflamação/tratamento farmacológico , Luteolina/farmacologia , Luteolina/uso terapêutico
3.
J Biol Regul Homeost Agents ; 26(3): 319-26, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-23034251

RESUMO

Mast cells are granulated hematopoietic cells derived from stem cells that reside in nearly all tissues and are involved in protection of a host from bacterial infection with a protective and pathogenic activity. Mast cells are important for both innate and adaptive immunity in tissues which are in close contact with the environment. These cells express proinflammatory cytokines such as IL-1, IL-6, IL-8 and tumor necrosis factor which are necessary for innate immunity. Mast cells also produce interleukin-9 and enhance mast cell expression of several cytokines including IL-1beta, IL-5, IL-6, IL-9 and IL-13. In addition, IL-9 can induce mast cell production of TGF-beta which can have proinflammatory downstream effects. IL-9 can function as either a positive or a negative regulator of immune responses and can have a detrimental role in allergy and autoimmunity. Furthermore, IL-9 contributes to disease by promoting mast cell expansion and production of IL-13 which in turn contributes to airway hyperresponsiveness. Here, in this editorial we review the interrelationship between IL-9 and mast cells.


Assuntos
Imunidade Adaptativa , Autoimunidade , Imunidade Inata , Interleucina-9/imunologia , Mastócitos/imunologia , Hipersensibilidade Respiratória/imunologia , Animais , Citocinas/imunologia , Regulação da Expressão Gênica/imunologia , Humanos , Mastócitos/patologia , Hipersensibilidade Respiratória/patologia
4.
Int J Immunopathol Pharmacol ; 25(3): 573-81, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-23058007

RESUMO

Cancer cells invade surrounding tissues and metastasize to distant sites. Diet high in fat is a strong link to, and perhaps causes, a high incidence of tumours. Trans-fatty acid might impair the function and it could be involved in the development of cancer. Cholesterol is also strongly suspected to be involved in the development of tumours, therefore it is important for everyone to eat well, especially for people with cancer to prevent the body tissues from breaking down and helping to rebuild the normal tissue that may have been affected by the treatments. Factors secreted by adipocytes and macrophages such as TNF-alpha and other inflammatory proteins are involved in inflammation in cancer. In addition, MCSF which up-regulates adipocyte tissue is also important for the stimulation of fat cell proliferation and is expressed by human adipocytes. Many cytokines, such as IL-1, IL-6, IL-8, IL-32, IL-33 and MCP-1, are biomarkers for cancer and chronic diseases along with transcription factors NFκB and AP-1; these last two factors are important bioactive substances on the molecular mechanism of the control of genes which in turn affect cellular metabolism. In this paper we revisit the interrelationship between cancer and metabolism.


Assuntos
Dieta/efeitos adversos , Neoplasias/prevenção & controle , Estado Nutricional , Comportamento de Redução do Risco , Animais , Dieta Hiperlipídica/efeitos adversos , Humanos , Neoplasias/epidemiologia , Neoplasias/fisiopatologia , Medição de Risco , Fatores de Risco
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA